Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases.
Laura AlderGloria BroadwaterMichelle GreenAmanda E D Van SwearingenEric S LippJeffrey Melson ClarkeCarey K AndersSarah SammonsPublished in: Neuro-oncology advances (2024)
This study illustrates the feasibility of detecting alterations from ctDNA among patients with BrMs. A higher frequency of actionable mutations was observed in ctDNA in patients with BrMs. Additional studies comparing ctDNA and alterations in BrMs tissue are needed to determine if ctDNA can be considered a surrogate to support treatment decisions.